Merck & Co., Inc. reported 13 holdings worth US$526M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 7, 2026
Merck & Co., Inc. reported 13 holdings worth US$526M as of Jun 30, 2026. Largest: Personalis, Inc., Moderna, Inc. and Kymera Therapeutics, Inc. Filed Aug 7, 2026 (Form 13F).
- Holdings
- 13
- Value as reported
- US$526M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Personalis, Inc. | 14M | US$188M | 35.8% |
| Moderna, Inc. | 2.31M | US$162M | 30.7% |
| Kymera Therapeutics, Inc. | 772K | US$88.5M | 16.8% |
| Aktis Oncology, Inc. | 953K | US$30.7M | 5.8% |
| Eikon Therapeutics, Inc. | 1.67M | US$21.7M | 4.1% |
| Entrada Therapeutics, Inc. | 1.74M | US$12.8M | 2.4% |
| Sutro Biopharma, Inc. | 272K | US$9.04M | 1.7% |
| Alector, Inc. | 3.55M | US$7.13M | 1.4% |
| Viridian Therapeutics, Inc. | 93,414 | US$1.72M | 0.33% |
| Xilio Therapeutics, Inc. | 106K | US$1.02M | 0.19% |
| Tuhura Biosciences, Inc. | 19,445 | US$45,501 | <0.01% |
| Neuphoria Therapeutics Inc. | 10,027 | US$43,818 | <0.01% |